Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

Published bySabina Cox Modified over 7 years ago

Similar presentations

Presentation on theme: "A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,"— Presentation transcript:

1 A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo, MSc, Noemí Reguart, MD, PhD, Miquel Taron, PhD, Eva Castellà, MD, Mariona Llatjós, MD, Carlota Costa, PhD, Clara Mayo, PhD, Anna Pradas, MSc, Cristina Queralt, MSc, Mónica Botia, María Pérez-Cano, Esther Carrasco, MSc, Mireia Tomàs, MSc, Jose Luis Mate, MD, Teresa Moran, MD, Rafael Rosell, MD, PhD  Journal of Thoracic Oncology  Volume 3, Issue 11, Pages (November 2008) DOI: /JTO.0b013e318189f579 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A, Example of length analysis for a wild-type (top panel) and a mutated patient (bottom panel) for exon 19 of EGFR. The peaks corresponding to the samples are represented in blue, the molecular weight markers (75, 100, 139, 150, and 160 bp) in orange. The mutated patient harbors a 15-bp deletion. B, Example of Taqman assay for a subset of patients. The two green triangles correspond to the H1975 cell line and to a tumor harboring the L858R mutation. The red circles correspond to the PC-9 cell line and to several wild-type tumors. The gray squares are negative and extraction controls. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318189f579) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Example of response to erlotinib (patient 13 in Table 3) harboring exon 19 delL746–A750, detected in pleural fluid. Top panel: CT scan prior to erlotinib treatment (A) and after 1 year of erlotinib treatment (B). Bottom panel: plain chest radiograph before erlotinib treatment (C) and after 1 year of erlotinib treatment (D). Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318189f579) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Sequencing chromatogram for EGFR exons 19 and 20 in a patient progressing to erlotinib (patient A in Table 4) showing heterogeneous distribution of the T790M mutation. Four areas of the tumor mass at the site of progression (PB1, PB2, PB3, and PB4) were analyzed. Top panel: length analysis for exon 19; the 104-kb peak showing the presence of a 15-bp deletion is indicated by an arrow. Bottom panel: sequencing results for exon 20; the presence of the T790M mutation as an additional T peak in the chromatogram is indicated with an asterisk. While the primary mutation (the 15-bp deletion delE746–A750) was present in all areas, the T790M mutation (C to T transition) was not detected in one area of the tumor (PB1). The result was confirmed by TaqMan assay. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318189f579) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE S1 Sensitivity of the assay: Serially diluted genomic DNA from the cell lines PC-9 (harboring a deletion in exon 19) and H1975 (harboring both the T790M and the L858R mutations) was analyzed (A and C). Ten picogram of DNA were successfully amplified and the corresponding mutations detected. We also trypsinized tumor cells in culture, extended them on a slide and microdissected them in different quantities. Four tumor cells were sufficient to determine EGFR mutation status (B and D). Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318189f579) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE S1 Sensitivity of the assay: Serially diluted genomic DNA from the cell lines PC-9 (harboring a deletion in exon 19) and H1975 (harboring both the T790M and the L858R mutations) was analyzed (A and C). Ten picogram of DNA were successfully amplified and the corresponding mutations detected. We also trypsinized tumor cells in culture, extended them on a slide and microdissected them in different quantities. Four tumor cells were sufficient to determine EGFR mutation status (B and D). Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318189f579) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE S1 Sensitivity of the assay: Serially diluted genomic DNA from the cell lines PC-9 (harboring a deletion in exon 19) and H1975 (harboring both the T790M and the L858R mutations) was analyzed (A and C). Ten picogram of DNA were successfully amplified and the corresponding mutations detected. We also trypsinized tumor cells in culture, extended them on a slide and microdissected them in different quantities. Four tumor cells were sufficient to determine EGFR mutation status (B and D). Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318189f579) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

8 FIGURE S1 Sensitivity of the assay: Serially diluted genomic DNA from the cell lines PC-9 (harboring a deletion in exon 19) and H1975 (harboring both the T790M and the L858R mutations) was analyzed (A and C). Ten picogram of DNA were successfully amplified and the corresponding mutations detected. We also trypsinized tumor cells in culture, extended them on a slide and microdissected them in different quantities. Four tumor cells were sufficient to determine EGFR mutation status (B and D). Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318189f579) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,"

Similar presentations

Volume 206, Issue 3, Pages (March 2013)

Volume 206, Issue 3, Pages (March 2013)
A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA  Tomomi Nakamura, MD, Naoko.

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA  Tomomi Nakamura, MD, Naoko.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Rapid Detection of the Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer for Analysis of Acquired Resistance Using Molecular Beacons 

Rapid Detection of the Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer for Analysis of Acquired Resistance Using Molecular Beacons 
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients  Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.

An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients  Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.
Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC  Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC  Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,
A Multiplex SNaPshot Assay as a Rapid Method for Detecting KRAS and BRAF Mutations in Advanced Colorectal Cancers  Sandrine Magnin, Erika Viel, Alice.

A Multiplex SNaPshot Assay as a Rapid Method for Detecting KRAS and BRAF Mutations in Advanced Colorectal Cancers  Sandrine Magnin, Erika Viel, Alice.
Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 
A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,
Comparison of Allelic Discrimination by dHPLC, HRM, and TaqMan in the Detection of BRAF Mutation V600E  Pablo Carbonell, María C. Turpin, Daniel Torres-Moreno,

Comparison of Allelic Discrimination by dHPLC, HRM, and TaqMan in the Detection of BRAF Mutation V600E  Pablo Carbonell, María C. Turpin, Daniel Torres-Moreno,
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,
MET Mutation Associated with Responsiveness to Crizotinib

MET Mutation Associated with Responsiveness to Crizotinib
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Similar presentations

Ads by Google